Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer

Journal of Molecular Cell Biology

Volumn 4, Issue 3, 2012, Pages 164-173

  Choi, Jin Woo ^a,b   Lee, Jeong Won ^c   Kim, Jun Ki ^b   Jeon, Hye Kyung ^c   Choi, Jung Joo ^c   Kim, Dae Gyu ^a   Kim, Byoung Gie ^c   Nam, Do Hyun ^c   Kim, Hong Joong ^d   Yun, Seok Hyun ^b   Kim, Sunghoon ^a,e  

^a Seoul National University   (South Korea)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Neomics Co Ltd   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

AIMP2; chemoresistant cancer; multi tRNA synthetase complex; NF B; ovarian cancer; splicing variant

Indexed keywords

AIMP2 DX2; CISPLATIN; I KAPPA B; PACLITAXEL; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ABDOMEN; ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; CELL GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; ENDOSCOPY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NF-KAPPA B; OVARIAN NEOPLASMS; RNA SPLICING; RNA, SMALL INTERFERING; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861860617     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjs018     Document Type: Article

References (32)

1. Ak, P., and Levine, A.J. (2010). p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism. FASEB J. 24, 3643-3652.
2. Balkwill, F. (2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25, 409-416.
3. Charles, K.A., Kulbe, H., Soper, R., et al. (2009). The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 119, 3011-3023.
4. Chen, R., Alvero, A.B., Silasi, D.A., et al. (2007). Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am. J. Reprod. Immunol. 57, 93-107.
5. Choi, J.W., Kim, D.G., Park, M.C., et al. (2009a). AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2. J. Cell Sci. 122, 2710-2715.
6. Choi, J.W., Um, J.Y., Kundu, J.K., et al. (2009b). Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis. Carcinogenesis 30, 1638-1644.
7. Choi, J.W., Kim, D.G., Lee, A.E., et al. (2011). Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis. PLoS Genet. 7, e1001351.
8. Dey, A., Tergaonkar, V., and Lane, D.P. (2008). Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat. Rev. Drug Discov. 7, 1031-1040.
9. Dobrzycka, B., Terlikowski, S.J., Garbowicz, M., et al. (2009). Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer. Folia Histochem. Cytobiol. 47, 609-613.
10. Eltabbakh, G.H. (2004). Recent advances in the management of women with ovarian cancer. Minerva Ginecol. 56, 81-89.
11. Han, J.M., Park, B.J., Park, S.G., et al. (2008). AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53. Proc. Natl Acad. Sci. USA 105, 11206-11211.
12. Hernandez, L., Hsu, S.C., Davidson, B., et al. (2010). Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 70, 4005-4014.
13. Hsu, H., Shu, H.B., Pan, M.G., et al. (1996). TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84, 299-308.
14. Janssens, S., Tinel, A., Lippens, S., et al. (2005). PIDD mediates NF-kappaB activation in response to DNA damage. Cell 123, 1079-1092.
15. Karin, M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436.
16. Kim, M.J., Park, B.J., Kang, Y.S., et al. (2003). Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat. Genet. 34, 330-336.
17. Kwong, J., Chan, F.L., Wong, K.K., et al. (2009). Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 11, 529-541.
18. Lee, S.Y., Reichlin, A., Santana, A., et al. (1997). TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 7, 703-713.
19. Leeman, J.R., and Gilmore, T.D. (2008). Alternative splicing in the NF-kappaB signaling pathway. Gene 423, 97-107.
20. Liu, Z.G. (2005). Molecular mechanism of TNF signaling and beyond. Cell Res. 15, 24-27.
21. Liu, G.H., Wang, S.R., Wang, B., et al. (2006). Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int. J. Gynecol. Cancer 16, 1777-1782.
22. McGuire, W.P., Hoskins, W.J., Brady, M.F., et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6.
23. Micheau, O., and Tschopp, J. (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181-190.
24. Nakanishi, C., and Toi, M. (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5, 297-309.
25. Rho, S.B., Kim, M.J., Lee, J.S., et al. (1999). Genetic dissection of proteinprotein interactions in multi-tRNA synthetase complex. Proc. Natl Acad. Sci. USA 96, 4488-4493.
26. Sethi, G., Sung, B., Kunnumakkara, A.B., et al. (2009). Targeting TNF for treatment of cancer and autoimmunity. Adv. Exp. Med. Biol. 647, 37-51.
27. Sood, A.K., and Buller, R.E. (1998). Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet. Gynecol. 92, 312-319.
28. Tada, K., Okazaki, T., Sakon, S., et al. (2001). Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death. J. Biol. Chem. 276, 36530-36534.
29. Tazi, J., Bakkour, N., and Stamm, S. (2009). Alternative splicing and disease. Biochim. Biophys. Acta 1792, 14-26.
30. Wang, C.Y., Cusack, J.C., Jr., Liu, R., et al. (1999). Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5, 412-417.
31. Xia, Z.P., and Chen, Z.J. (2005). TRAF2: a double-edged sword? Sci. STKE 2005, pe7.
32. Xiao, W. (2004). Advances in NF-kappaB signaling transduction and transcription. Cell Mol. Immunol. 1, 425-435.